Huadong Medicine recently published its 2013 interim report. During the reporting period, the business of pharmaceutical production and medicine distribution of Huadong Medicine continued to grow steadily. All operating indicators had fulfilled the expected targets. During the reporting period, the revenue of Huadong Medicine totaled RMB8,105.24 million, representing an increase of 15.03% as compared with the corresponding period of the previous year; its total profit amounted to RMB530.57 million, representing an increase of 29.73% as compared with the corresponding period of the previous year; and its net profit attributable to its parent company amounted to RMB332.88 million, representing an increase of 31.19% as compared with the corresponding period of the previous year.

During the reporting period, the parent company of Huadong Medicine recorded a revenue of RMB5,755.71 million, representing an increase of 15.27% as compared with the corresponding period of the previous year, and realized net profit of RMB87.22 million (excluding investment gain), representing an increase of 18.37% as compared with the corresponding period of the previous year. During the same period, Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. (杭州中美华东制药有限公司), a subsidiary of Huadong Medicine, recorded a revenue of RMB1,423.118 million, representing an increase of 21.08% as compared with the corresponding period of the previous year; and recorded net profit of RMB298.1487 million, representing an increase of 23.43% as compared with the corresponding period of the previous year.